ATR and neoplasm: AZD6738, a specific ATR inhibitor, has been demonstrated to potentiate radiation-induced lymphocyte infiltration and lymphocyte activation in tumor tissues, thus achieving a more potent anticancer effect.16 17 Moreover, AZD6738 is currently under investigations in 10 clinical trials in combination with either chemotherapy or radiotherapy.